Hypertension Clinical Trial
Official title:
Effects of a Reduction in Renal Function on Cardiovascular Structure and Function: A 5 Year Study of Kidney Donors.
Chronic kidney disease (CKD) is present in 1 in 7 of the population and confers a high risk
of cardiovascular disease. The pathophysiology of cardiovascular disease in CKD is poorly
understood because CKD is always accompanied by confounding factors including the underlying
disease process (e.g. diabetes mellitus, systemic vasculitis) and the consequences of CKD
including hypertension, anaemia and inflammation.
Nephrectomy in kidney donors causes a 30% reduction in renal function providing an ideal
study population to measure prospectively the effects of reduced kidney function on the
cardiovascular system.
The CRIB-Donor study (ClinicalTrials.gov Identifier:NCT01028703) demonstrated adverse effects
on cardiovascular structure and function at 12 months compared to controls including an
increase in left ventricular mass. This proposal will measure the changes in cardiovascular
structure and function, cardiovascular age and biochemical changes at 5 years providing
information on the long term effects of reduced renal function.
A reduction in renal function at one year in kidney donors is associated with adverse
cardiovascular structural and functional changes. Increases in LV mass and perhaps fibrosis
along with increased arterial stiffness are associated with adverse changes in prognostic
imaging biomarkers and may in the long term contribute to the development of clinical disease
such as heart failure and arrhythmia.
It is important to follow this valuable and well characterised cohort of subjects to
investigate the further natural history of these cardiovascular effects and determine whether
such changes tend to regress, stabilise or worsen over time.
Hypotheses:
The reduction in GFR occurring after surgical uni-nephrectomy in donors is associated with
long term adverse cardiac and vascular effects which include:
1. A sustained increased in left ventricular mass, impaired left ventricular systolic and
diastolic function and increased left ventricular interstitial fibrosis.
2. Reduced aortic distensibility.
3. Increased systolic but not diastolic blood pressure.
4. Increases in oxidative stress, inflammation and collagen turnover
5. Cardiovascular ageing as evidenced by adverse effects on telomere length and DNA damage.
Study design:
We aim to follow up all 124 patients who originally took part in the CRIB-DONOR study at 5
years and eventually 10 years post nephrectomy.
Statistics and sample size:
Using the effect sizes and variances from our previous work (change in LV mass 7g, SD of
change 10g) we calculate that by studying 50 subjects in each group we will have 93% power to
detect a difference in LV mass of 7g with an alpha value of 0.05. Due to the nature of a
follow up study some drop out can be expected. A minimum of 34 patients is required in each
group in order to achieve an 80% power. This effect is clinically important; a fall in LV
mass index of one SD has been shown to be associated with a 38% reduction in cardiovascular
mortality.
With respect to telomere shortening, assuming mean and SD of base pair length of 5500 and 530
the study will be able to detect a difference of 0.612 SD, i.e. 324 base pairs. A sample size
of 50 patients per group would provide a 85% power to detect a difference.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |